Understanding NIPT in Pregnancy
Understanding Non-Invasive Prenatal Testing (NIPT) in the UK: A Comprehensive Guide
In recent years, prenatal care has advanced significantly, offering expectant parents diverse options to check their unborn child’s health including the option of non invasive prenatal testing blood test (NIPT). Non-Invasive Prenatal Testing (NIPT) is a screening method that has gained popularity for its ability to detect certain genetic conditions early in pregnancy with minimal risk. This guide explores what NIPT is, how it works, its benefits, how it compares with the traditional Combined Test, and provides brief notes on several common chromosomal and genetic conditions.
What is NIPT?
Non-Invasive Prenatal Testing (NIPT) is a screening test that analyses small fragments of fetal DNA circulating in a pregnant woman’s blood.
Unlike invasive procedures such as amniocentesis or chorionic villus sampling (CVS), which carry a small risk of miscarriage, NIPT only needs a blood sample from the mother. This makes it a safer choice for screening for chromosomal abnormalities like Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13).
How Does NIPT Work?
NIPT works by examining cell-free fetal DNA (cffDNA) that originates from the placenta and is present in the mother’s bloodstream. This DNA can be extracted and tested for chromosomal abnormalities. The test is usually done between the 10th and 14th weeks of pregnancy, with results available within one to two weeks.
It is crucial to remember that NIPT is a screening test, not a diagnostic one. While it can indicate the likelihood of certain conditions, it cannot confirm a diagnosis. Positive results from NIPT are usually followed by diagnostic tests such as amniocentesis or CVS to confirm the findings.
NIPT vs. The Combined Test
The Combined Test is a traditional first-trimester screening method that is offered on the NHS and assesses the risk of chromosomal abnormalities. It combines a blood test measuring levels of certain proteins and hormones in the mother’s blood with an ultrasound scan that measures the nuchal translucency (the fluid at the back of the baby’s neck). The Combined Test is typically performed between the 11th and 14th weeks of pregnancy and can identify 85% of pregnancies affected by Down Syndrome, Edward Syndrome and Patau Syndrome. It won’t screen for anything else.
While both NIPT and the Combined Test are used to screen for conditions like Down syndrome, there are significant differences between them:
– Accuracy: NIPT is more accurate than the Combined Test, with a detection rate of over 99% for Down syndrome, compared to around 85-90% for the Combined Test.
– Risk: NIPT is non-invasive and poses no risk to the fetus, while the Combined Test, although non-invasive, may lead to a higher chance of further invasive testing if results indicate a higher risk.
– Timing and Procedure: NIPT can be done as early as 10 weeks and involves just a blood test, while the Combined Test is done later and requires both a blood test and an ultrasound scan.
– Scope: The Combined Test provides a general risk assessment, while NIPT specifically analyses fetal DNA, making it more targeted.
Who Should Consider NIPT?
NIPT is often recommended for women considered at higher risk for chromosomal abnormalities. This includes:
– Women aged 35 or older
– Those with a family history of genetic disorders
– Pregnancies identified as high-risk due to abnormal ultrasound findings
– Women with a previous pregnancy affected by a chromosomal condition
However, NIPT is increasingly available to all pregnant women who seek additional reassurance about their baby’s health and may be helpful in pregnancies with abnormal scan findings.
The Benefits of NIPT
NIPT’s non-invasive nature is its most significant benefit, posing no risk to the fetus. Its accuracy is another advantage, particularly for detecting Down syndrome, with a detection rate surpassing 99%. Furthermore, NIPT allows for early detection, giving parents more time to consider their options and prepare for the arrival of a child with special needs if necessary. In some cases it may be combined with carrier testing to provide an even wider range of screening – See Medicover Veragene Test
Limitations and Considerations
Despite its benefits, NIPT has limitations. It is a screening test and cannot provide a definitive diagnosis. False positives and negatives, while rare, can occur, necessitating follow-up diagnostic tests for confirmation.
NIPT also does not cover all genetic conditions, focusing mainly on common chromosomal abnormalities. Parents should discuss with their healthcare provider what conditions the test will screen for and consider the potential emotional impact of the results. Counselling and support are essential for parents facing positive results or difficult decisions about their pregnancy.
Common Chromosomal and Genetic Conditions Detected by NIPT
NIPT and other prenatal screening methods can help identify the likelihood of several chromosomal and genetic conditions. Below is a brief overview of some of these conditions:
1. Down Syndrome (Trisomy 21)
Down Syndrome is the most common chromosomal condition, occurring in about 1 in 700 births. It is caused by an extra copy of chromosome 21 and is associated with intellectual disability, characteristic facial features, and a higher risk of certain health problems such as heart defects and respiratory issues. Early intervention and supportive care can help individuals with Down syndrome lead fulfilling lives.
2. Edwards Syndrome (Trisomy 18)
Edwards Syndrome, or Trisomy 18, occurs in approximately 1 in 5,000 live births and is caused by an extra copy of chromosome 18. It is associated with severe developmental delays, congenital heart defects, and other life-threatening organ abnormalities. Unfortunately, many infants with Edwards Syndrome do not survive beyond the first year of life.
3. Patau Syndrome (Trisomy 13)
Patau Syndrome, or Trisomy 13, is a rare condition occurring in about 1 in 16,000 live births, caused by an extra copy of chromosome 13. This condition results in severe intellectual disabilities, heart defects, and physical abnormalities such as cleft palate and extra fingers or toes. Like Edwards Syndrome, Patau Syndrome often leads to a very short life expectancy.
4. Turner Syndrome (Monosomy X)
Turner Syndrome occurs in females when one of the X chromosomes is missing or partially missing, affecting about 1 in 2,500 female births. It is characterized by short stature, delayed puberty, infertility, and sometimes heart defects or learning difficulties. With proper medical care and hormone therapies, individuals with Turner Syndrome can live healthy lives.
5. 22q11.2 Deletion Syndrome (DiGeorge Syndrome)
22q11.2 Deletion Syndrome, also known as DiGeorge Syndrome, occurs when a small piece of chromosome 22 is missing. This condition affects about 1 in 4,000 live births and can cause a wide range of symptoms, including heart defects, immune system deficiencies, cleft palate, and developmental delays. The severity of symptoms varies, and early diagnosis and intervention can significantly improve outcomes.
6. Triploidy
Triploidy is a rare and usually fatal condition in which a baby has three sets of chromosomes instead of the usual two, resulting in 69 chromosomes instead of 46. This condition is typically found in early pregnancy and often leads to miscarriage. If the pregnancy continues to term, the baby is usually born with severe abnormalities and does not survive long after birth. Only the Panorama NIPT Test can screen for Triploidy.
EXPRESS – TDL Veriseq Express NIPT (UK)
Non-invasive prenatal testing (NIPT) screens for the presence of specific chromosome disorders in the developing fetus. The TDL Veriseq Express NIPT analyses fragments of DNA in maternal plasma that have been released from both maternal and placental cells with results in 2-4 days.
TDL Versieq express NIPT requires a single blood draw, which poses no threat to the fetus, and can be done as early as 10 weeks’ gestation. By analysing the proportions of DNA fragments derived from different chromosomes or chromosome regions, NIPT can screen for the presence or absence of specific chromosome disorders.
NIPT is more accurate than first trimester maternal serum screening and ultrasound in identifying pregnancies with or without these disorders.
DNA from the fetus circulates in the mother’s blood. Cell-free DNA (cfDNA) results from the natural breakdown of fetal cells (presumed to be mostly placental) and clears from the maternal system within hours of giving birth.
During a pregnancy, cfDNA can be tested to give the most accurate screening approach in estimating the risk of a fetus having a common chromosome condition sometimes called a trisomy. This occurs when there are three copies of a particular chromosome instead of the expected two. The test looks to detect the following conditions:
- Trisomy 21 is the most common trisomy at the time of birth. Also called Down syndrome, it is associated with moderate to severe intellectual disabilities and may also lead to digestive disease, congenital heart defects and other malformations.
- Trisomy 18 (Edwards syndrome) and Trisomy 13 (Patau syndrome) are associated with a high rate of miscarriage. These babies are born with severe brain abnormalities and often have congenital heart defects as well as other birth defects. Most affected individuals die before or soon after birth, and very few survive beyond the first year of life.
- Sex chromosome conditions occur when there is a missing, extra, or incomplete copy of the X or Y chromosomes. The NIPT test with sex chromosome aneuploidy panel option can assess risk for XXX, XYY, XXY (Klinefelter syndrome), and a missing X chromosome in a girl (Turner syndrome).
In addition, NIPT can assess fetal sex. This is optional (no additional cost).
NIPT does not screen for non-chromosome disorders, familial mutations, malformations, fetal growth or fetal viability.
What will it screen for?
- Down syndrome/trisomy 21
- Edwards Syndrome/Trisomy 18
- Patau Syndrome/Trisomy 13
- Sex chromosome aneuploidies
- Turner syndrome/monosomy X
- Klinefelter Syndrome/XXY
- Triple X/XXX Syndrome
- Jacobs Syndrome/XYY
- Gender information
Click here to learn more about the TDL Veriseq Express NIPT Test!
CORE – Natera Panorama NIPT Test (UK)
The Natera Panorama NIPT Test by Natera is one of the most widely recognized NIPT options. It is unique in that it analyzes both maternal and fetal DNA, which may enhance the test’s accuracy. Panorama is capable of screening for a broad range of chromosomal conditions, including common trisomies, microdeletions such as 22q11.2 deletion syndrome, triploidy, and sex chromosome aneuploidies.
Features of the Panorama Test
– Accuracy: Panorama offers over 99% sensitivity and specificity for Down syndrome and other common trisomies.
– SNP Technology: Panorama uses single nucleotide polymorphism (SNP) technology to differentiate between maternal and fetal DNA more accurately, potentially improving detection rates.
– Broad Screening: Panorama can screen for a range of conditions, including microdeletions and sex chromosome abnormalities, providing a more comprehensive analysis than some other NIPT options.
What will it screen for?
- Down syndrome/trisomy 21
- Edwards Syndrome/Trisomy 18
- Patau Syndrome/Trisomy 13
- Sex chromosome aneuploidies
- Turner syndrome/monosomy X
- Klinefelter Syndrome/XXY
- Triple X/XXX Syndrome
- Jacobs Syndrome/XYY
- Di George Syndrome / 22q11.2 deletion
- Triploidy
- Gender information
Click here to learn more about the Natera Panorama NIPT Test!
COMPREHENSIVE – Medicover VERAgene NIPT Test with Carrier Screening (UK)
The Medicover VERAgene NIPT Test by Medicover is the only non-invasive prenatal test that can simultaneously screen for aneuploidies (Down Syndrome, Edward Syndrome and Patau Syndrome) , microdeletions and single gene diseases. The diseases screened by VERAgene are associated with moderate to severe impact on the baby’s health and development with significant impact on the quality of life.
By combining detection of aneuploidies and microdeletions with the screening of monogenic diseases, VERAgene provides a comprehensive solution to prospective parents. The test requires a maternal blood sample and a cheek swab (buccal swab) from the baby’s dad. The test will work for single and twin pregnancies, IVF including donor egg pregnancies and vanishing twin.
Click the link to learn more about the VERAgene 100 Single Gene Diseases Panel which includes Cystic Fibrosis, Sickle Cell Disease, B-Thalassaemia.
VERAgene needs a maternal blood sample, and a buccal swab sample from the biological father. The maternal blood contains cell-free DNA from both the mother and the fetus. This cell-free DNA is isolated and analysed along with the father’s DNA sample for any potential genetic mutations using next generation sequencing. Sophisticated bioinformatics algorithms are then used to compute the risk of the fetus having a monogenic disease. In short it combines an NIPT Test with a Carrier Screen.
What will it screen for?
- Down syndrome/trisomy 21
- Edwards Syndrome/Trisomy 18
- Patau Syndrome/Trisomy 13
- Sex chromosome aneuploidies
- Turner syndrome/monosomy X
- Klinefelter Syndrome/XXY
- Triple X/XXX Syndrome
- Jacobs Syndrome/XYY
- Di George Syndrome / 22q.11.2 deletion
- Additional 100 single gene disorders like cystic fibrosis, Sickle Cell Disease, B-Thalassaemia
- Gender information
Click here to learn more about the Medicover VERAgene NIPT Test!
PREMIUM – GenePlanet Lumipeek Premium NIPT ad GenePlanet Pro NIPT Test (UK)
GenePlanet Lumipeek Premium NIPT Test and GenePlanet Pro NIPT Test are the only genome-wide Non-Invasive Prenatal Test (NIPT) in the UK that provides near karyotype level information. Most NIPTs, such as Harmony, Panorama focus on a limited number of specific chromosomes such as chromosome 13, 18 21 and the two sex chromosomes to screen for conditions like Down Syndrome, Edward Syndrome, Patau Syndrome and Turner Syndrome and some may also detect specific microdeletions like 22q11 deletion, (Di George Syndrome) and other rare abnormalities in other chromosomes. Unlike most NIPTs, the GenePlanet Lumipeek Premium NIPT Test and GenePlanet Pro NIPT Test analyse EACH chromosome in the baby to detect extra or missing parts (duplications, deletions) or whole chromosome changes. It has > 99% proven detection rate for most common trisomies based on a study of nearly 147,000 pregnancies and globally more than 10,000,000 pregnant women all over the world have already had the NIPT by GenePlanet test.
What will it screen for?
- Down syndrome/trisomy 21
- Edwards Syndrome/Trisomy 18
- Patau Syndrome/Trisomy 13
- Sex chromosome aneuploidies
- Turner syndrome/monosomy X
- Klinefelter Syndrome/XXY
- Triple X/XXX Syndrome
- Jacobs Syndrome/XYY
- Di George Syndrome / 22q.11.2 deletion
- Additional 92 Deletion and Duplication Syndromes
- Gender information
Click here to learn more about the GenePlanet Lumipeek Premium NIPT Test from Illumina!
Click here to read more about the GenePlanet Pro NIPT Test from BGI
PREMIUM – Labcorp Maternit Genome Test (USA)
As of September 2024 the Maternit Genome test by Labcorp is no longer available in the UK.
The MaterniT Genome test is one of the most advanced NIPT options currently available in the USA. This test provides comprehensive screening for common trisomies, sex chromosome abnormalities, and other genetic conditions, including microdeletions. It is the one of the few NIPT tests in USA that screens ALL the chromosomes and will detect about 30% more genetic conditions than any other NIPT Test. In the UK the GenePlanet Lumipeek Premium NIPT Test and GenePlanet Pro NIPT Test is similar.
Conclusion
Non-Invasive Prenatal Testing is a significant advancement in prenatal care, offering expectant parents a safer and more accurate choice than traditional methods like the Combined Test for screening chromosomal abnormalities. However, it is vital to understand its limitations and to use it in conjunction with professional medical advice.
Both NIPT and the Combined Test have their roles in prenatal care, and the choice of which to use should be made based on individual circumstances, risk factors, and personal preferences. Through informed discussions with healthcare providers, parents can make the best decision for themselves and their unborn child, fully aware of the conditions that can be detected and the implications of those findings.
The TDL Veriseq Express NIPT test provides rapid and accurate screening for the most common chromosomal abnormalities such as Down Syndrome, Edward Syndrome, Patau Syndrome. Sex Chromosome Aneuploidy and optionally includes the gender.
The Natera Panorama NIPT Test is an ideal screening test for most pregnancies and can detect Triploidy and can distinguish between maternal and fetal DNA so very useful in twins.
The Medicover VERAgene NIPT Test is currently one the best general screening tests in the UK as it screens for Down Syndrome, Edward Syndrome, Patau Syndrome. Sex Chromosome Aneuploidy, microdeletions such as 22q Deletion Syndrome and 100 single gene disorders including Cystic Fibrosis, Sickle Cell Disease and B-Thalassaemia.
The GenePlanet Lumipeek Premium NIPT Test and GenePlanet Pro NIPT Test are however the most comprehensive NIPT tests currently available in the UK at present as they screen for duplications and deletions in ALL the chromosomes down to a resolution similar to a karyotype ie better than 7mb.
#NIPT #nipttest #downsyndrome #edwardsyndrome #Patausyndrome #Natera #panoramatest
#GenePlanet #Lumipeek #Genometest #Medicover #VERAgene
Leave a Reply
Want to join the discussion?Feel free to contribute!